A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING THE PHARMACOKINETICS, EFFICACY AND SAFETY OF MULTIPLE SWITCHES BETWEEN USTEKINUMAB AND ABP 654 COMPARED WITH CONTINUED USE OF USTEKINUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Intervention/treatment:
ABP 654
Medical condition:
PLAQUE PSORIASIS
Protocol code:
20200417
Control number:
248870
Status:
Closed
Approved:
February 26, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04761627
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Amgen Inc.
Phone:
866-572-6436
Sponsor
AMGEN INC

Locations

British Columbia

Enverus Medical Research
Surrey, British Columbia, V3V 0C6

Manitoba

Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, R3M 3Z4

New Brunswick

Dr. Irina Turchin PC Inc.
Fredericton, New Brunswick, E3B 1G9

Ontario

CCA Medical Research
Ajax, Ontario, L1S 7K8
Dermatology Ottawa Research Centre
Ottawa, Ontario, K2C 3N2
DermEdge Research Inc.
Mississauga, Ontario, L4Y 4C5
Dr. S. K. Siddha Medicine Professional Corporation - Doctor's Office
Newmarket, Ontario, L3Y 5G8
Dr Wei Jing Loo Medicine Professional Corporation
London, Ontario, N6H 5L5
Guelph Dermatology Research
Guelph, Ontario, N1L 0B7
K. Papp Clinical Research Inc.
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc
Markham, Ontario, L3P 1X3
North York Research Inc. - Dermatology
North York, Ontario, M2M 4J5
Research Toronto
Toronto, Ontario, M4W 2N4
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, L4M 7G1

Results

See the results from the trial NCT04761627. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?